Lates News

According to AI Fast News, Minsheng Securities released a research report on April 24th, giving Xinlitai (002294.SZ) a "buy" rating. The reasons for the rating mainly include: 1) Innovative drugs have become the core growth driver, with a well-laid out layout in the hypertension field; 2) Phase II clinical trials of JK07 for chronic heart failure are being simultaneously conducted in China and the U.S., with data expected to be released; 3) Research and development pipeline steadily advancing: multiple projects entering the late clinical stage. (Daily Economic News)